A Phase 2 interventional study of AKB-6548 in Anemia and Kidney Disease, sponsored by Akebia Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-07-01.
Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.
Among the 27 studies testing vadadustat in Anemia, this one is the 22nd largest by enrollment, is the only one that started in 2010, is one of 8 in phase 2, and was the 1st registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:
Mackay Memorial Hospital
Ages 18+
vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2010.
This study's enrollment of 10 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 60 across the 27 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 27 have an industry lead sponsor. The 4 most frequent:
Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.
23 studies in Anemia by Akebia Therapeutics: none open now, none under way, none of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 23 studies in Anemia by Akebia Therapeutics, this one is the 18th largest by enrollment, is the only one that started in 2010, is one of 9 in phase 2, and was the 1st registered.
Akebia Therapeutics’s Anemia studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing vadadustat in Anemia, from their registry updates:
Among Akebia Therapeutics’s 23 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, pharmacodynamics and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis participants with anemia.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AKB-6548
Different dose levels
Mean Change From Baseline in Hemoglobin (Hgb) on Day 29
Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates that hemoglobin concentration increased.
Time frame: Baseline; Day 29
Mean Change From Baseline in Hematocrit on Day 29
Blood samples were collected to assess hematocrit. A positive change from baseline indicates hematocrit concentration increased.
Time frame: Baseline; Day 29
Mean Change From Baseline in Total Red Blood Cell (RBC) Count on Day 29
Blood samples were collected to assess RBC count. Baseline RBC count was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates RBC count increased.
Time frame: Baseline; Day 29
Mean Change From Baseline in Absolute Reticulocyte Count on Day 29
Blood samples were collected to assess reticulocyte count. Baseline absolute reticulocyte count was defined as the average of the 3 reticulocyte counts obtained prior to dosing (Screening, Pre- Baseline, and Baseline). A positive change from baseline indicates absolute reticulocyte count increased.
Time frame: Baseline; Day 29
Mean Change From Baseline in Reticulocyte Hemoglobin (Hgb) Content on Day 29
Blood samples were collected to assess reticulocyte Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates reticulocyte Hgb content increased.
Time frame: Baseline; Day 29
Number of Participants With Absolute Change From Baseline in Hemoglobin (Hgb) at Day 29
Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).
Time frame: Day 29
Number of Participants With the Percentage Change From Baseline in Hemoglobin (Hgb) at Day 29
Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).
Time frame: Day 29
Number of Participants With Percentage Change From Baseline in Hematocrit at Day 29
Blood samples were collected to assess hematocrit.
Time frame: Day 29
Number of Participants With Percentage Change From Baseline in Red Blood Cell (RBC) Count at Day 29
Blood samples were collected to assess RBC count. Baseline RBC count was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).
Time frame: Day 29
Number of Participants With Change From Baseline in Absolute Reticulocyte Count at Day 29
Blood samples were collected to assess reticulocyte count. Baseline absolute reticulocyte count was defined as the average of the 3 reticulocyte counts obtained prior to dosing (Screening, Pre- Baseline, and Baseline).
Time frame: Day 29
Change From Baseline in Ferritin on Day 29
Blood samples were collected to assess ferritin. A positive change from baseline indicates ferritin content increased.
Time frame: Baseline; Day 29
Change From Baseline in Iron on Day 29
Blood samples were collected to assess iron. A positive change from baseline indicates iron content increased.
Time frame: Baseline; Day 29
Change From Baseline in Total Iron Binding Capacity on Day 29
Blood samples were collected to assess total iron binding capacity. A positive change from baseline indicates total iron binding capacity increased.
Time frame: Baseline; Day 29
Change From Baseline in Transferrin Saturation on Day 29
Blood samples were collected to assess transferrin saturation. The transferrin saturation is the ratio of the serum iron concentration and the total iron-binding capacity, expressed as a percentage. A positive change from baseline indicates transferrin saturation increased.
Time frame: Baseline; Day 29
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An Adverse Event (AE) was defined as any untoward medical occurrence, signs, symptoms, disease, or laboratory or physiological observations occurring in a participant administered with drug, regardless of a causal relationship with that treatment or usage. This also included all suspected adverse medication reactions, reactions from medication overdose, abuse, withdrawal, sensitivity, toxicity, unrelated illnesses, including worsening a pre-existing condition, injury, or accidents. Serious Adverse Events (SAEs) was defined as any life-threatening condition; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or death.
Time frame: Up to 2 weeks post 28 days of treatment
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
Parameters assessed for laboratory values included hematology, chemistry, urinalysis, and coagulation. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to 2 weeks post 28 days of treatment
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values
Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to 2 weeks post 28 days of treatment
Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.
Time frame: Up to 2 weeks post 28 days of treatment
Mean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected).
Time frame: Up to 2 weeks post 28 days of treatment
Mean Trough Concentrations of Vadadustat at Day 8, 15, 22 and 29
Serum samples were collected from the participants at the defined time points. Trough concentration was defined as the concentration of drug in the blood immediately before the next dose is administered. Trough concentration was calculated using the validated liquid chromatography-mass spectrometry (LC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) method
Time frame: Pre-dose at Day 8, 15, 22 and 29
| Milestone | Vadadustat |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates that hemoglobin concentration increased.
| Grams per decilitre (g/dL) | Vadadustat |
|---|---|
| Baseline | 9.91 ± 0.63 |
| Change from Baseline on Day 29 | 0.63 ± 0.46 |
Blood samples were collected to assess hematocrit. A positive change from baseline indicates hematocrit concentration increased.
| Percentage of red blood cells in blood | Vadadustat |
|---|---|
| Baseline | 30.43 ± 2.69 |
| Change from Baseline on Day 29 | 1.62 ± 1.71 |
Blood samples were collected to assess RBC count. Baseline RBC count was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates RBC count increased.
| Million cells per cubic millimeter | Vadadustat |
|---|---|
| Baseline | 3.313 ± 0.389 |
| Change from Baseline on Day 29 | 0.167 ± 0.170 |
Blood samples were collected to assess reticulocyte count. Baseline absolute reticulocyte count was defined as the average of the 3 reticulocyte counts obtained prior to dosing (Screening, Pre- Baseline, and Baseline). A positive change from baseline indicates absolute reticulocyte count increased.
| Cells per Microlitre | Vadadustat |
|---|---|
| Baseline | 51076.00 ± 24975.76 |
| Change from Baseline on Day 29 | 18647.00 ± 18289.84 |
Blood samples were collected to assess reticulocyte Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates reticulocyte Hgb content increased.
| Picograms | Vadadustat |
|---|---|
| Baseline | 31.49 ± 2.44 |
| Change from Baseline on Day 29 | 0.13 ± 0.84 |
Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).
| Participants | Vadadustat |
|---|---|
| Change from baseline ≥ 0.4 grams per decilitre | 6 |
| Change from baseline ≥ 0.6 grams per decilitre | 5 |
| Change from baseline ≥ 0.8 grams per decilitre | 3 |
| Change from baseline ≥ 1.0 grams per decilitre | 2 |
Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).
| Participants | Vadadustat |
|---|---|
| Percent change from Baseline ≥ 5.0% | 5 |
| Percent change from Baseline ≥ 7.5% | 3 |
| Percent change from Baseline ≥ 10.0% | 3 |
Blood samples were collected to assess hematocrit.
| Participants | Vadadustat |
|---|---|
| Percent change from Baseline ≥ 5.0% | 6 |
| Percent change from Baseline ≥ 7.5% | 2 |
| Percent change from Baseline ≥ 10.0% | 2 |
Blood samples were collected to assess RBC count. Baseline RBC count was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).
| Participants | Vadadustat |
|---|---|
| Percent change from Baseline ≥ 5.0% | 5 |
| Percent change from Baseline ≥ 7.5% | 3 |
| Percent change from Baseline ≥ 10.0% | 3 |
Blood samples were collected to assess reticulocyte count. Baseline absolute reticulocyte count was defined as the average of the 3 reticulocyte counts obtained prior to dosing (Screening, Pre- Baseline, and Baseline).
| Participants | Vadadustat |
|---|---|
| Change from Baseline ≥ 6000 cells per microlitre | 8 |
| Change from Baseline ≥ 12000 cells per microlitre | 7 |
| Change from Baseline ≥ 18000 cells per microlitre | 6 |
Blood samples were collected to assess ferritin. A positive change from baseline indicates ferritin content increased.
| Nanograms per millilitre | Vadadustat |
|---|---|
| Baseline | 324.0 ± 199.2 |
| Change from Baseline on Day 29 | -52.3 ± 36.6 |
Blood samples were collected to assess iron. A positive change from baseline indicates iron content increased.
| Micrograms per decilitre | Vadadustat |
|---|---|
| Baseline | 69.4 ± 18.4 |
| Change from Baseline on Day 29 | -8.2 ± 20.3 |
Blood samples were collected to assess total iron binding capacity. A positive change from baseline indicates total iron binding capacity increased.
| Micrograms per decilitre | Vadadustat |
|---|---|
| Baseline | 266.4 ± 56.4 |
| Change from Baseline on Day 29 | 43.4 ± 34.8 |
Blood samples were collected to assess transferrin saturation. The transferrin saturation is the ratio of the serum iron concentration and the total iron-binding capacity, expressed as a percentage. A positive change from baseline indicates transferrin saturation increased.
| Percentage | Vadadustat |
|---|---|
| Baseline | 26.1 ± 6.3 |
| Change from Baseline on Day 29 | -6.4 ± 5.4 |
An Adverse Event (AE) was defined as any untoward medical occurrence, signs, symptoms, disease, or laboratory or physiological observations occurring in a participant administered with drug, regardless of a causal relationship with that treatment or usage. This also included all suspected adverse medication reactions, reactions from medication overdose, abuse, withdrawal, sensitivity, toxicity, unrelated illnesses, including worsening a pre-existing condition, injury, or accidents. Serious Adverse Events (SAEs) was defined as any life-threatening condition; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or death.
| Participants | Vadadustat |
|---|---|
| TEAEs | 5 |
| SAEs | 0 |
| Deaths | 0 |
Parameters assessed for laboratory values included hematology, chemistry, urinalysis, and coagulation. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Vadadustat |
|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values | 0 |
Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Vadadustat |
|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values | 0 |
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.
| Participants | Vadadustat |
|---|---|
| Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings | 0 |
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected).
| Milliseconds | Vadadustat |
|---|---|
| Baseline PR Interval | 183.2 ± 42.6 |
| Change from Baseline PR Interval | -4.4 ± 18.1 |
| Baseline QT Interval | 415.6 ± 45.7 |
| Change from Baseline QT Interval | 1.4 ± 20.3 |
| Baseline QRS Interval | 95.4 ± 21.4 |
| Change from Baseline QRS Interval | 3.4 ± 6.7 |
| Baseline QTC Interval | 429.9 ± 30.5 |
| Change from Baseline QTC Interval | 4.1 ± 8.3 |
Serum samples were collected from the participants at the defined time points. Trough concentration was defined as the concentration of drug in the blood immediately before the next dose is administered. Trough concentration was calculated using the validated liquid chromatography-mass spectrometry (LC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) method
| nanograms per millilitre | Vadadustat |
|---|---|
| Day 8 | 3260.6 ± 2763.8 |
| Day 15 | 3826.3 ± 2537.5 |
| Day 22 | 3667.4 ± 1933.4 |
| Day 29 | 5622.4 ± 5385.4 |
Collected over Up to 2 weeks post 28 days of treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vadadustat | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Event | Vadadustat |
|---|---|
| DiarrhoeaGastrointestinal disorders | 2/10 |
| ConstipationGastrointestinal disorders | 1/10 |
| DyspepsiaGastrointestinal disorders | 1/10 |
| NauseaGastrointestinal disorders | 1/10 |
| ChillsGeneral disorders | 1/10 |
| FatigueGeneral disorders | 1/10 |
| Decreased appetiteMetabolism and nutrition disorders | 1/10 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/10 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/10 |
| DizzinessNervous system disorders | 1/10 |
Full Analysis Set: All participants who received at least 1 dose of study medication. Per the protocol, all results data are summarized as a single treatment arm (i.e., all participants receiving Vadadustat); no separate analysis was performed to report results by disease state.
| Age, Continuous(years) | Vadadustat |
|---|---|
| Mean | 60.1 ± 11.8 |
| Sex: Female, Male(Participants) | Vadadustat |
|---|---|
| Female | 5 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | Vadadustat |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Vadadustat |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Kidney disease stage(Participants) | Vadadustat |
|---|---|
| Stage 3 | 6 |
| Stage 4 | 4 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Oct 2010, a primary completion of Apr 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2022, 11 years 2 months after primary completion. A results delay was requested in Sep 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat